Orient Pharma Co. Ltd.
Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based… Read more
Orient Pharma Co. Ltd. (4166) - Total Liabilities
Latest total liabilities as of June 2024: NT$831.38 Million TWD
Based on the latest financial reports, Orient Pharma Co. Ltd. (4166) has total liabilities worth NT$831.38 Million TWD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Orient Pharma Co. Ltd. - Total Liabilities Trend (2019–2023)
This chart illustrates how Orient Pharma Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Orient Pharma Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Orient Pharma Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SBI Investment KOREA Co. Ltd
KQ:019550
|
Korea | ₩4.14 Billion |
|
1ST SUMMIT BANCORP of Johnstown Inc
PINK:FSMK
|
USA | $1.41 Billion |
|
Etteplan Oyj
HE:ETTE
|
Finland | €181.83 Million |
|
Klingelnberg AG
SW:KLIN
|
Switzerland | CHF158.99 Million |
|
Groupe Sfpi
PA:SFPI
|
France | €317.26 Million |
|
Oregon Pacific Bancorp
PINK:ORPB
|
USA | $734.10 Million |
|
BitFuFu Inc. Class A Ordinary Shares
NASDAQ:FUFU
|
USA | $282.19 Million |
|
Scicom MSC Bhd
KLSE:0099
|
Malaysia | RM37.09 Million |
Liability Composition Analysis (2019–2023)
This chart breaks down Orient Pharma Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Orient Pharma Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Orient Pharma Co. Ltd. (2019–2023)
The table below shows the annual total liabilities of Orient Pharma Co. Ltd. from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | NT$892.18 Million | +17.76% |
| 2022-12-31 | NT$757.65 Million | +16.94% |
| 2021-12-31 | NT$647.90 Million | +23.08% |
| 2020-12-31 | NT$526.41 Million | +32739.30% |
| 2019-12-31 | NT$1.60 Million | -- |